The MHRA position, summarised by Lynda Scammell (head of borderline products at the MHRA) and reported in The Guardian on 4 April 2026, is that products which are sold for human use or which carry medicinal claims fall inside the Human Medicines Regulations 2012, and that the MHRA is investigating UK clinics making such claims about unregulated peptide products
Nevertheless, employers understand that coverage for weight-loss medications is a valuable perk for attracting and retaining talented staff
These GI effects are typically temporary and most common during the first 4 to 8 weeks of treatment and often resolve as the body adjusts
Client Experience : By educating clients on how to naturally boost GLP-1 through dietary choices and intermittent fasting, Ray has seen improvements in their weight loss efforts, better blood sugar control, and more consistent energy levels during training
Aim for 8,000 to 10,000 steps daily as a baseline
Patients were randomized to one of four treatment arms: saxagliptin 5 mg + metformin HCl immediate-release 500 mg, saxagliptin 10 mg + metformin HCl immediate-release 500 mg, saxagliptin 10 mg + placebo, or metformin HCl immediate-release 500 mg + placebo (the maximum recommended approved saxagliptin dose is 5 mg daily